ArticleInternational journal of preventive medicine2014
Hepatitis G virus exposure in dialysis patients and blood donors in Isfahan-Iran.
Article in International journal of preventive medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 syntheses or guidelines pooled it, 3 citations in OpenAlex.
- Global epidemiology of hepatitis B virus infection in dialysis patients: a systematic review and meta-analysis of prevalence, immunity, risk factors, and beyond.International urology and nephrology · 2026Pooled it
- Epidemiology of hepatitis C virus among hemodialysis patients in the Middle East and North Africa: systematic syntheses, meta-analyses, and meta-regressions.Epidemiology and infection · 2017Pooled it
- Molecular prevalence and genotypic distribution of human pegivirus-1 among Iranian hemodialysis patients.Virus research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundHepatitis G virus (HGV) is transmitted mainly by parenteral route and patients on maintenance hemodialysis (HD) are at risk for this infection. This study was conducted to estimate prevalence of infection through the presence of anti-HGV and to evaluate the clinical significance of HGV envelope protein E2 (anti-E2) in HD patients in compare with volunteer blood donors in Isfahan-Iran.
methodsIn a cross-sectional study, a total of 40 HD patients as cases and 40 healthy volunteer blood donors as negative controls were selected randomly in summer 2008. The epidemiological data were obtained in all subjects, and duration of HD was obtained in HD patients as well. All samples were tested for anti-E2 antibodies, hepatitis C virus (HCV)-antibody and hepatitis B virus surface antigen (HBs-Ag) by an enzyme-linked immunosorbent assay and a recombinant immunoblot assay was employed to confirm anti-HCV reactivity. Student's t-test, Chi-square test or Fisher exact test was used for data analysis and P < 0.05 was considered as statistically significant.
resultsTen of the 40 HD patients tested positive for anti-E2 (25%) and of 40 voluntary blood donors, 10 (5%) were positive for anti-E2 (P = 0.012). Anti-HCV antibodies and HBs-Ag were found in 4 and 1 HD patients, respectively. In anti-E2-positive patients, co-infection with HCV or hepatitis B virus was not significant. Furthermore, the mean duration of hemodialysis in anti-E2 positive and anti-E2 negative patients did not have significant differences.
conclusionsHD patients are at increased risk of HGV infection in Isfahan-Iran. Since hepatitis G is a good predictor for parenteral transmission, it is suggested to test all of the blood for transfusion for HGV infection.
Indexed as
Identifiers
26622993PMC4635412W2258752356What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.